Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
04/19/18

Once-daily Single Inhaler Triple Therapy Superior to Relvar/Breo Ellipta and Anoro Ellipta Across Multiple Endpoints Including Exacerbations, Lung Function and Quality of Life DUBLIN , April 19, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today

04/17/18

Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor Antibiotics Against Difficult-to-Treat Staphylococcus aureus Pathogens including Challenging

03/21/18
DUBLIN , March 21, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the 17 th Annual Needham Healthcare Conference on Wednesday, March 28, 2018 , at 9:00 a.m.
02/27/18
Multiple Programs Poised to Advance in 2018 DUBLIN , Feb. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (" Theravance Biopharma " or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2017 .
02/20/18
DUBLIN , Feb. 20, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended December 31, 2017 after market close on Tuesday, February 27, 2018 .
02/15/18
DUBLIN , Feb. 15, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted the submission of the landmark IMPACT study data to the European Medicines Agency (EMA) as part of a type II variation to support an expanded label for Trelegy Ellipta in
02/07/18
Theravance Biopharma Together with Janssen will Jointly Develop and Commercialize TD-1473, a Novel, Potent, Orally Administered and Intestinally Restricted pan-Janus Kinase (JAK) Inhibitor Theravance Biopharma Eligible to Receive up to $1 Billion in Potential Payments, Including $100 Million
01/29/18
FDA Assigns PDUFA Target Action Date of November 13, 2018 DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Jan. 29, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that the U.S.
11/28/17
DUBLIN , Nov. 28, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted the filing of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration ( FDA ) for the use of Trelegy Ellipta, the triple combination therapy
11/21/17
DUBLIN , Nov. 21, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 8:00 a.m. ET .